Press Releases

Date Title  
Toggle Summary Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences in March
─ Cowen and Company 36 th Annual Health Care Conference ─ ─ Barclays Capital Global Healthcare Conference ─ ─ Webcasts Available Through Aimmune Corporate Website ─ BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 1, 2016-- Aimmune Therapeutics, Inc.
Toggle Summary Aimmune Therapeutics to Announce Fourth Quarter and Full Year 2015 Financial Results on Thursday, March 3, 2016
— Webcast and Conference Call to Follow — BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 25, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that its financial results for the fourth quarter and full
Toggle Summary Aimmune Therapeutics Announces Presentation at the 2016 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
— Aimmune Late-Breaking Abstract Posted Online Today by The Journal of Allergy and Clinical Immunology (JACI) — — Dr. J. Andrew Bird Will Present Data on the Efficacy and Safety of AR101 for the Treatment of Peanut Allergy from the ARC002 Phase 2 Follow-On Trial — BRISBANE, Calif.
Toggle Summary Aimmune Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference
— Presentation on Monday, February 8, 2016 , at 9:00 a.m. ET — BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 1, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that CEO Stephen Dilly , M.B.B.S., Ph.D.,
Toggle Summary Aimmune Therapeutics Enrolls First Patient in Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy
— Aimmune Provides Year-End Update and Upcoming Milestones Review — BRISBANE, Calif. --(BUSINESS WIRE)--Jan. 11, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, announced today that it has enrolled the first
Toggle Summary Aimmune Therapeutics to Present at the 34th Annual J.P. Morgan Healthcare Conference
— Presentation on Thursday, January 14, 2016 , at 11:00 a.m. Pacific Time — BRISBANE, Calif. --(BUSINESS WIRE)--Jan. 6, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that CEO Stephen Dilly ,
Toggle Summary Aimmune Therapeutics Appoints Jeffrey H. Knapp as Chief Operating Officer
— Operational Leadership and Deep Commercial Experience Key as Aimmune Launches Pivotal Phase 3 PALISADE Clinical Trial — BRISBANE, Calif. --(BUSINESS WIRE)--Dec. 17, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food
Toggle Summary Aimmune Therapeutics to Present at the Piper Jaffray 27th Annual Healthcare Investor Conference
— Presentation on December 1, 2015 , at 2:00 p.m. ET — BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 16, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that it will present at the Piper Jaffray 27th
Toggle Summary Aimmune Therapeutics Reports Positive Findings for ARC002 Follow-On Phase 2 Study of AR101 for Treatment of Peanut Allergy
— Aimmune Plans to Release Full ARC002 Data at AAAAI Meeting in March 2016 — BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 11, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced positive findings for its
Toggle Summary Aimmune Therapeutics Announces Financial Results for the Third Quarter 2015
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 4, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced financial results for the third quarter and nine months ended September 30, 2015 .